Aktuellt
SENASTE
We already knew that the clinical program for FG001 would take a little longer, due to its unexpectedly strong clinical profile as an imaging agent, but we now have clarity on what it means for the timeline, with potential approval pushed back until 2025, though the commercial opportunity remains essentially unchanged.
LÄS MER
